Valuation: Moderna, Inc.

Market Cap 28.77B 25.26B 23.25B 21.66B 40.86B 2,735B 41.69B 280B 108B 1,342B 108B 106B 4,672B P/E 2026 *
-8.4x
P/E 2027 * -15.5x
Enterprise Value 25.16B 22.09B 20.33B 18.95B 35.73B 2,392B 36.46B 245B 94.76B 1,174B 94.47B 92.43B 4,087B EV / Sales 2026 *
12x
EV / Sales 2027 * 10.5x
Free-Float
92.69%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Moderna, Inc.

1 day+8.03%
1 week+31.38%
Current month+12.09%
1 month+72.00%
3 months+59.55%
6 months+154.37%
Current year+166.19%
1 week 59.23
Extreme 59.23
81.4
1 month 45.3
Extreme 45.3
81.4
Current year 29.81
Extreme 29.81
81.4
1 year 22.28
Extreme 22.28
81.4
3 years 22.28
Extreme 22.28
170.47
5 years 22.28
Extreme 22.28
497.49
10 years 11.54
Extreme 11.54
497.49
Manager TitleAgeSince
Chief Executive Officer 54 01/03/2011
Director of Finance/CFO 49 06/09/2022
President 50 01/11/2024
Director TitleAgeSince
Chairman 63 01/02/2012
Director/Board Member 54 01/03/2011
Director/Board Member 69 11/12/2019
Date Insider Type Main position Quantity % Market Cap.
06-15Fiscal year

Chairperson

160,008 0.0403%
06-05Fiscal year

Chief Financial Officer

29,301 0.0074%
06-05Fiscal year

General Counsel

29,301 0.0074%
Change 5-day change 1-year change 3-year change Capi.($)
+7.79%+31.38%+159.25%-35.51% 28.77B
+3.03%+3.20%+16.84%-10.87% 63.56B
+2.37%+2.92%+58.43%+232.12% 55.92B
+0.36%+39.60%+39.60%+39.60% 41.68B
-0.52%+0.08%-50.89%-57.38% 39.12B
+3.76%+7.06%+62.34%-24.25% 30.97B
+3.86%+9.95%+73.43%+90.45% 22.74B
+7.22%+12.16%+7.63%+184.50% 17.64B
+1.50%+1.06%+66.43%+128.15% 16.66B
+2.24%+9.31%+77.85%+339.05% 14.6B
Average +3.18%+4.95%+51.09%+88.58% 33.16B
Weighted average by Cap. +2.84%+3.98%+43.89%+67.29%

Financials

2026 *2027 *
Net sales 2.09B 1.84B 1.69B 1.58B 2.97B 199B 3.03B 20.34B 7.88B 97.67B 7.86B 7.69B 340B 2.53B 2.22B 2.04B 1.9B 3.59B 240B 3.66B 24.58B 9.52B 118B 9.5B 9.29B 411B
Net income -3.4B -2.98B -2.75B -2.56B -4.82B -323B -4.92B -33.02B -12.79B -159B -12.76B -12.48B -552B -1.82B -1.6B -1.47B -1.37B -2.59B -173B -2.64B -17.74B -6.87B -85.15B -6.85B -6.7B -296B
Net Debt -3.61B -3.17B -2.91B -2.72B -5.12B -343B -5.23B -35.05B -13.58B -168B -13.54B -13.25B -586B -2.27B -2B -1.84B -1.71B -3.23B -216B -3.3B -22.11B -8.57B -106B -8.54B -8.36B -369B
Logo Moderna, Inc.
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows: - revenue from product sales (96.1%); - revenue from collaboration agreements (1.5%); - revenue from royalties and licensing (1.3%); - revenue from grants (1.1%). At the end of 2024, the group's portfolio comprises 37 products in clinical development, of which 10 in phase I, 18 in phase II and 9 in phase III, 3 products in preclinical development, and 4 products in commercial phase. Net sales are distributed geographically as follows: the United States (55.1%), Europe (18.5%) and other (26.4%).
Employees
4,700
Date Price Change Volume
02/07/26 $77.80 +7.31% 6,595,719
01/07/26 $72.50 +3.53% 9,275,292
30/06/26 $70.03 +0.47% 11,805,910
29/06/26 $69.70 +3.61% 8,077,421
26/06/26 $67.27 +12.59% 14,456,655
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
24
Last Close Price
72.50USD
Average target price
45.85USD
Spread / Average Target
-36.76%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MRNA Stock